Capsid Titer

Antibodies bind proteins on the viral capsid, producing a measurable assay signal. That signal is compared with the response from a reference standard, allowing the concentration of capsid-containing particles in the preparation to be estimated. This approach connects molecular recognition of capsid proteins with a quantitative measurement used in viral-vector characterization.

A reference standard provides the comparison needed to translate an immunoassay signal into an estimated particle concentration. Without that benchmark, the signal would indicate antibody binding but would not directly support standardized concentration reporting. Using a reference also helps bioengineering teams compare preparations and maintain consistent measurements during viral-vector development and manufacturing.

Capsid titer counts capsid-containing particles, whereas genome titer reflects the packaged nucleic acid measurement. Because some capsids may lack a nucleic acid payload, the two values do not necessarily match. Measuring both gives a broader characterization of the preparation and supports estimation of the relationship between total particles and payload-containing particles.

A capsid measurement includes particles whether or not they contain the intended nucleic acid payload. Consequently, a high capsid concentration does not by itself establish how many particles are payload-containing. Pairing capsid and genome measurements provides the information needed to estimate full-to-empty particle ratios and interpret preparation quality more meaningfully.

The preparation is analyzed with an immunoassay in which antibodies recognize capsid proteins. The resulting signal is then evaluated against a reference standard, and the comparison is used to estimate particle concentration. This workflow makes capsid measurement practical for characterizing viral-vector preparations while linking the assay result to a standardized concentration value.

Manufacturing teams can use the measurement to assess particle concentration during viral-vector production and to evaluate product quality. Comparing capsid results across preparations helps identify consistency in the manufactured material. The measurement also supports assessment of purification and formulation steps, where particle concentration and composition are important for controlling the final preparation.

Together, the measurements show both the total capsid-containing particle concentration and the nucleic acid-related content of a preparation. Their comparison helps estimate full-to-empty particle ratios, which informs interpretation of material used for dosing. These data also support formulation optimization and more consistent dose standardization across viral-vector preparations.